

APPENDIX

Claims 60, 65-69, 71, 72, and 82-85 are amended as shown below:

- 60. (Amended) A method for treating a B cell [malignancy] leukemia comprising administering a therapeutically effective amount [off] of:
- (i) an anti-CD20 antibody having B-cell depleting activity, or a fragment thereof having B-cell depleting activity; and
 - (ii) an anti-CD40L antibody that antagonizes interaction of CD40 and CD40L, or a fragment thereof that antagonizes interaction of CD40 and CD40L.

65. (Amended) The method of claim [61] 60 wherein said B cell leukemia is selected from the group consisting of chronic B cell leukemia, acute lymphoblastic leukemia, chronic lymphocytic[,] leukemia, and Burkitt's type leukemia [and monocytic cell leukemia].

66. (Amended) The method of claim 60 wherein said anti-CD20 antibody is [Rituxan®] a humanized, primatized, or chimeric anti-CD20 antibody.

67. (Amended) The method of claim 60 wherein said anti-CD40L antibody is a humanized, primatized, or chimeric anti-CD40L antibody.

68. (Amended) The method of claim 67 wherein said anti-CD40L antibody is [I?DEC-131] humanized MAb 89-76 or humanized MAb 24-31.

69. (Amended) The method of claim 60 wherein said [anti-Cd20] anti-CD20 antibody is radiolabeled with ⁹⁰Y.

71. (Amended) The method of claim 60, which [includes the administration of] further comprises administering at least one alkylating chemotherapeutic agent.

72. (Amended) The method of claim 71 wherein said alkylating chemotherapeutic agent is selected from the group consisting of [vincristine, prednisone, anthracycline, cyclophosphamide, asparaginase, fludarabine monophosphate, 2-chlorodeoxy adenosine, pertostate, metrotrexate, chlorambicil, 2-CDA, 2'-deoxy-coformycin, cytosine

arabinoside, cisplatin, etoposide, procarbazine ifosfamide] cyclophosphamide, chlorambicil, procarbazine, and lomustine.

82. (Amended) The method of claim 80 wherein the anti-CD20 antibody is [Rituxan®] IDEC-C2B8 and the anti-CD40L antibody is humanized MAb 24-31.

83. (Amended) The method of claim 81 wherein the anti-CD20 antibody is Rituxan® IDEC-C2B8 and the anti-CD40L antibody is humanized MAb 24-31.

84. (Amended) The method of claim 80 which [includes chemotherapy] further comprises administering at last one alkylating chemotherapeutic agent.

85. (Amended) The method of claim [80] 81 which [includes chemotherapy] further comprises administering at last one alkylating chemotherapeutic agent. --